Business Wire (Free subscription) | 11/13/2009
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced the previously announced offering of $350,000,000 aggregate principal amount of 2.15% Senior Notes due 2012 and $400,000,000 aggregate principal amount of 3.25% Senior Notes due 2014 at an issue price of 99.855% of the principal amount of the 2012 notes and 99.904% of the principal...
Business Wire (Free subscription) | 11/13/2009
CHICAGO--(BUSINESS WIRE)--Fitch Ratings has assigned an 'A-' rating to Thermo Fisher Scientific Inc.'s (Thermo Fisher) proposed new three- and five-year unsecured notes. In addition, Fitch has upgraded Thermo Fisher's existing ratings as follows: --Issuer Default Rating (IDR) to 'A-' from 'BBB+'; --Senior unsecured debt to 'A-' from 'BBB+'; --Subordinated debt to 'BBB+' from 'BBB'. The...
Business Wire (Free subscription) | 11/13/2009
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it intends to offer senior notes for the purpose of refinancing certain of its outstanding indebtedness. The notes are being sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and...
Business Wire (Free subscription) | 11/13/2009
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has commenced a tender offer to purchase for cash any and all of its outstanding 2.50% Convertible Senior Notes due 2023. The company also announced today that it has called for redemption all of its outstanding 6¾% Senior Subordinated Notes due...
DeviceSpace (Free subscription) | 11/10/2009
Boston Business Journal -- Inverness Medical Innovations has terminated a distribution agreement with Thermo Fisher Scientific Inc. involving its suite of Biosite diagnostic products, opting instead to deliver the health-care devices and tests directly to consumers.
GuruFocus Updates (Free subscription) | 10/30/2009
By 10qk. Thermo Fisher Scientific Inc. ( TMO ) filed Quarterly Report for the period ended 2009-09-26. Read more » »
Medical News Today (Free subscription) | 10/28/2009
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the availability in Europe of its new Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI), commonly known as a heart attack. Copeptin, developed by recently acquired B.R.A.H.M.S.
Boston Globe (Free subscription) | 12/05/2009
A unit of Waltham’s Thermo Fisher Scientific Inc. has sued a Woburn competitor, charging it deliberately misrepresented the radiation risks of some of Thermo’s highest-profile products: portable analyzers that scan toys to detect lead before they reach store shelves.
The Boston Business Journal (Free subscription) | 11/13/2009
Scientific instrument maker Thermo Fisher Scientific Inc. announced it is refinancing some of its debt by selling senior notes and offering to redeem or exchange notes that are currently outstanding. (TMO)
bizjournals (Free subscription) | 11/10/2009
Inverness Medical Innovations has terminated a distribution agreement with Thermo Fisher Scientific Inc. involving its suite of Biosite diagnostic products, opting instead to deliver the health-care devices and tests directly to consumers. (TMO) (IMA)
